Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protégé Encore: Teplizumab in Recent-Onset Type 1 Diabetes
NCT00920582Phase 3Terminated
- Sponsor
- MacroGenics
- Start
- Sep 2009
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by MacroGenics. Started Sep 2009; status: terminated.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00920582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920582.